Burden and Management of Multi-Drug Resistant Organism Infections in Solid Organ Transplant Recipients Across the World: A Narrative Review.
clinical impact
diagnosis and treatment
epidemiology
multidrug-resistant Gram-negative bacteria
new anti-infective agents
solid organ transplant
Journal
Transplant international : official journal of the European Society for Organ Transplantation
ISSN: 1432-2277
Titre abrégé: Transpl Int
Pays: Switzerland
ID NLM: 8908516
Informations de publication
Date de publication:
2024
2024
Historique:
received:
24
11
2023
accepted:
07
05
2024
medline:
2
7
2024
pubmed:
2
7
2024
entrez:
2
7
2024
Statut:
epublish
Résumé
Solid organ transplant (SOT) recipients are particularly susceptible to infections caused by multidrug-resistant organisms (MDRO) and are often the first to be affected by an emerging resistant pathogen. Unfortunately, their prevalence and impact on morbidity and mortality according to the type of graft is not systematically reported from high-as well as from low and middle-income countries (HIC and LMIC). Thus, epidemiology on MDRO in SOT recipients could be subjected to reporting bias. In addition, screening practices and diagnostic resources may vary between countries, as well as the availability of new drugs. In this review, we aimed to depict the burden of main Gram-negative MDRO in SOT patients across HIC and LMIC and to provide an overview of current diagnostic and therapeutic resources.
Identifiants
pubmed: 38952482
doi: 10.3389/ti.2024.12469
pii: 12469
pmc: PMC11215024
doi:
Substances chimiques
Anti-Bacterial Agents
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
12469Informations de copyright
Copyright © 2024 Freire, Pouch, Manesh and Giannella.
Déclaration de conflit d'intérêts
AM received scientific grants from the Wellcome Trust DBT alliance and the Indian Council of Medical Research. MG received a research grant from Pfizer, payment for lecture from Shionogi, MSD, Pfizer and BioMerieux. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.